Cognition Therapeutics, Inc. (CGTX)

Market Cap	40.31M
Revenue (ttm)	n/a
Net Income (ttm)	-22.71M
Shares Out	30.31M
EPS (ttm)	-0.86
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,240
Open	1.28
Previous Close	1.28
Day's Range	1.28 - 1.43
52-Week Range	1.07 - 3.51
Beta	n/a
Analysts	Strong Buy
Price Target	9.00 (+576.69%)
Earnings Date	Nov 13, 2023

About CGTX

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer's disease. The company is also developing COG0201 SHINE, a randomized double-blind and placebo-controlled for ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 8, 2021
• Employees: 22
• Stock Exchange: NASDAQ
• Ticker Symbol: CGTX

Analyst Forecast

According to 3 analysts, the average rating for CGTX stock is "Strong Buy." The 12-month stock price forecast is $9.0, which is an increase of 576.69% from the latest price.

Price Target

$9.0

(576.69% upside)

Analyst Consensus: Strong Buy